SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Lampertico, Pietro ^{[3
]}

Lim, Young-Suk ^{[4
]}

Agarwal, Kosh ^{[5
]}

Fung, Scott K. ^{[6
]}

Tsang, Owen ^{[7
]}

Elkhashab, Magdy ^{[8
]}

Kao, Jia-Horng ^{[9
]}

Luis Calleja, Jose ^{[10
]}

Khalili, Mandana ^{[11
]}

Ravendhran, Natarajan ^{[12
]}

Tan, Susanna ^{[13
]}

Flaherty, John F. ^{[13
]}

Gaggar, Anuj ^{[13
]}

Lau, Audrey H. ^{[13
]}

Wu, George ^{[13
]}

Hann, Hie-Won L. ^{[14
]}

Pan, Calvin ^{[15
]}

Kim, Hyung Joon ^{[16
]}

Kennedy, Patrick T. F. ^{[17
]}

Chan, Henry Lik Yuen ^{[18
]}

机构：

[1] Hosp Gen Univ Valle Hebron, Barcelona, Spain

[2] Ciberehd, Barcelona, Spain

[3] Univ Milan, Gastroenterol & Hepatol, Fdn Irccs Ca Granda O Maggiore Policlin, Milan, Italy

[4] Univ Ulsan, Dept Gastroenterol, Ctr Liver, Asan Med Ctr,Coll Med, Ulsan, South Korea

[5] Kings Coll Hosp London, Inst Liver Studies, London, England

[6] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada

[7] Princess Margaret Hosp, Kwai Chung, 2-10 Princess Margaret Hosp Rd, Hong Kong, Peoples R China

[8] Toronto Liver Ctr, Res, Toronto, ON, Canada

[9] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

[10] Hosp Univ Puerta De Hierro, Majadahonda, Spain

[11] Univ Calif San Fransisco, San Francisco, CA USA

[12] Digest Dis Associates, Wyomissing, PA USA

[13] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[14] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[15] Calvin Q Pan Clin, New York, NY USA

[16] Chung Ang Univ, Coll Med, Seoul, South Korea

[17] Barts Hlth NHS Trust, London, England

[18] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：301A / 301A

页数：1

共 50 条

[1] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
Pan, Calvin Q.
Gane, Edward
Seto, Wai-Kay
Janssen, Harry L.
Caruntu, Florin
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Bae, Ho
Mo, Shuyuan
Suri, Vithika
Gaggar, Anuj
Flaherty, John F.
Kao, Jia-Horng
Brunetto, Maurizia Rossana
Buti, Maria
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
[2] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik-Yuen
Buti, Maria
Flisiak, Robert
Ryder, Stephen
Streinu-Cercel, Adrian
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Subramanian, G. Mani
Zoulim, Fabrian
Andreone, Pietro
Marcellin, Patrick
GUT, 2018, 67 : A97 - A97
[3] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF)
Ahn, Sang Hoon
Kao, Jia-Horng
Hann, Hie-Won
Scott, Fung
Trinh, Huy
Nguyen, Tuan Trong
Paik, Seung Woon
Gaggar, Anuj
Flaherty, John
Yee, Leland
Jump, Belinda
Sethi, Shalini
Wu, George
Chan, Carol Yee Kwan
GUT, 2020, 69 : A73 - A74
[4] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
Buti, Maria
Stepanova, Tatjana
Celen, Mustafa K.
Flisiak, Robert
Ryder, Stephen D.
Streinu-Cercel, Adrian
Gurel, Selim
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Mo, Shuyuan
Subramanian, Mani
Nurmukhametova, Elena
Zoulim, Fabien
Andreone, Pietro
Marcellin, Patrick
HEPATOLOGY, 2017, 66 : 488A - 488A
[5] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
Janssen, H.
Gane, E.
Seto, W-K
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Horban, A.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J.
Kao, J-H
Brunetto, M.
Ferret, M. B.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
[6] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
Gane, Edward
Seto, Wai Kay
Janssen, Harry L. A.
Caruntu, Florin A.
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Horban, Andrzej
Bae, Ho
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Oberle, Corinna
Mo, Shuyuan
Subramanian, G. Mani
Kao, Jia-Horng
Brunetto, Maurizia
Buti, Maria
SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
[7] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use
Gane, E.
Seto, W. K.
Janssen, H.
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Andrzej, H.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J. F.
Kao, J-H
Brunetto, M.
Buti Ferret, M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 43
[8] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
De Clercq, Erik
BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
[9] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik Yuen
Seto, Wai Kay
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GUT, 2019, 68 : A141 - A142
[10] Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
Gane, E.
Seto, W-K.
Janssen, H.
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Andrzej, H.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J. F.
Kao, J-H.
Brunetto, M.
Ferret, M. B.
JOURNAL OF HEPATOLOGY, 2018, 68 : S87 - S87

← 1 2 3 4 5 →